Compare Mutual Funds
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹500
-
Expense Ratio
2.39
-
NAV
₹9.46
-
Fund Started
06 Dec 2024
-
Fund Size
₹314.74 Cr
-
Exit Load
1% for redemption within 3 Months
-
1 Year
8.52%
-
3 Year
-
-
5 Year
-
-
Equity
95.11%
-
Cash
4.87%
-
Top 10 Holdings
Divi's Laboratories Ltd. | 8.90% |
Sun Pharmaceutical Industries Ltd. | 7.90% |
Apollo Hospitals Enterprise Ltd. | 6.20% |
Aurobindo Pharma Ltd. | 6.01% |
Piramal Pharma Ltd. | 4.00% |
Emcure Pharmaceuticals Ltd. | 3.91% |
Cipla Ltd. | 3.72% |
Neuland Laboratories Ltd. | 3.60% |
Fortis Healthcare Ltd. | 3.33% |
Rubicon Research Ltd. | 3.33% |
-
Name
-
-
Start Date
-
-
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
-
Launch Date
06 Dec 2024
-
